Biotechnology

Biotech

Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict

By Kate Sheridan

The Readout LOUD

Listen: Biogen’s big reveal, hot takes on Alzheimer’s, & the science of one-eyed sheep

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

Veritas, genetics company founded by George Church, suspends U.S. operations

By Kate Sheridan

Biotech

Detailed data on Biogen’s resurrected Alzheimer’s drug raise more questions than answers

By Rebecca Robbins and Matthew Herper

Biotech

Sage’s new antidepressant faces major setback in new study

By Matthew Herper and Adam Feuerstein

Biotech

Eli Lilly places the team from a startup it bought in January in charge of its cancer research

By Matthew Herper

Politics

More than 100 small biotech CEOs sound off against Pelosi’s signature drug pricing bill

By Nicholas Florko

Biotech

Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial

By Adam Feuerstein

Biotech

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

By Rebecca Robbins

Politics

Congress is hoping for another major medical research bill. But pharma’s not nearly as excited as before

By Nicholas Florko

Biotech

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

By Nicholas Florko

Biotech

Startup Spotlight: Juno, Vir alum starts a new immunotherapy company

By Kate Sheridan

Pharmalot

Pharmalittle: Feds probe drug makers for flooding communities with opioids; States proceeding with importation

By Ed Silverman

Biotech

Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

By Kate Sheridan

Biotech

Global Blood secures FDA approval for new pill to treat sickle cell disease

By Adam Feuerstein

Business

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

By Sharon Begley

Biotech

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By Matthew Herper

The Readout LOUD

Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

STAT Summit

Watch: The state of biotech at time of innovation — and high prices

By STAT staff

Biotech

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

By Adam Feuerstein

Biotech

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

By Kate Sheridan

Biotech

Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’

By Damian Garde

Biotech

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

By Kate Sheridan

Politics

12 burning questions for Stephen Hahn, Trump’s pick to lead FDA

By Nicholas Florko

Politics

Biotech venture capitalists form a lobbying coalition to join the drug pricing debate

By Nicholas Florko

biotechnology

Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

Careful stagecraft at Biogen’s big Alzheimer’s reveal cloaked deep divisions

Families are reeling after FDA rejects therapy for kids born without a thymus gland

Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict

Listen: Biogen’s big reveal, hot takes on Alzheimer’s, & the science of one-eyed sheep

Veritas, genetics company founded by George Church, suspends U.S. operations

Detailed data on Biogen’s resurrected Alzheimer’s drug raise more questions than answers

Sage’s new antidepressant faces major setback in new study

Eli Lilly places the team from a startup it bought in January in charge of its cancer research

More than 100 small biotech CEOs sound off against Pelosi’s signature drug pricing bill

Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

Congress is hoping for another major medical research bill. But pharma’s not nearly as excited as before

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

Startup Spotlight: Juno, Vir alum starts a new immunotherapy company

Pharmalittle: Feds probe drug makers for flooding communities with opioids; States proceeding with importation

Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

Global Blood secures FDA approval for new pill to treat sickle cell disease

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit

Watch: The state of biotech at time of innovation — and high prices

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

12 burning questions for Stephen Hahn, Trump’s pick to lead FDA

Biotech venture capitalists form a lobbying coalition to join the drug pricing debate